Table 4.

Association of diagnostic performance of ultrasound, MRI and positron emission tomography (PET)/CT with histopathological factors

Histological factor	Ultrasound		p-value	MRI		p-value	PET/CT		p-value
	Correct diagnosis	Incorrect diagnosis		Correct diagnosis	Incorrect diagnosis		Correct diagnosis	Incorrect diagnosis
Initial tumour size	3.75 ± 2.19	3.86 ± 2.27	0.792	3.6 ± 2.24	4.18 ± 2.17	0.153	4.3 ± 2.3	3.89 ± 2.15	0.371
Tumour size after neoadjuvant chemotherapy	1.65 ± 1.81	2.17 ± 2.21	0.133	1.74 ± 1.83	2.17 ± 2.3	0.24	1.95 ± 2.35	2.37 ± 2.04	0.343
Percentage diameter decrease	53.9 ± 39.48	45.8 ± 35.35	0.224	50.28 ± 38.96	49.12 ± 37.44	0.869	57.16 ± 42.92	37.85 ± 38.79	0.023*
Size of tumour deposit in lymph node	0.97 ± 0.63	0.5 ± 0.31	<0.001*	0.84 ± 0.61	0.57 ± 0.42	0.045*	1.09 ± 0.6	0.61 ± 0.49	0.002*
Perinodal tumour extension			0.709			0.329			0.904
Negative	16 (35.6%)	14 (31.8%)		19 (30.2%)	11 (40.7%)		7 (36.8%)	18 (35.3%)
Positive	29 (64.4%)	30 (68.2%)		44 (69.8%)	16 (59.3%)		12 (63.2%)	33 (64.7%)
Oestrogen receptor			0.009*			0.036*			0.061
Negative	30 (38.5%)	10 (17.5%)		32 (35.2%)	8 (17.8%)		16 (41%)	14 (23.3%)
Positive	48 (61.5%)	47 (82.5%)		59 (64.8%)	37 (82.2%)		23 (59%)	46 (76.7%)
Progesterone receptor			0.318			0.248			0.036*
Negative	41 (52.6%)	25 (43.9%)		48 (52.7%)	19 (42.2%)		24 (61.5%)	24 (40%)
Positive	37 (47.4%)	32 (56.1%)		43 (47.3%)	26 (57.8%)		15 (38.5%)	36 (60%)
HER2			0.183			0.716			0.044*
Negative	52 (66.7%)	44 (77.2%)		64 (70.3%)	33 (73.3%)		24 (61.5%)	48 (80%)
Positive	26 (33.3%)	13 (22.8%)		27 (29.7%)	12 (26.7%)		15 (38.5%)	12 (20%)
Nuclear grade			0.778			0.313			0.37
Low	28 (48.3%)	26 (51%)		34 (46.6%)	21 (56.8%)		10 (38.5%)	27 (49.1%)
High	30 (51.7%)	25 (49%)		39 (53.4%)	16 (43.2%)		16 (61.5%)	28 (50.9%)
Histological grade			0.071			0.262			0.008*
Low	33 (55.9%)	37 (72.5%)		44 (60.3%)	27 (71.1%)		11 (40.7%)	39 (70.9%)
High	26 (44.1%)	14 (27.5%)		29 (39.7%)	11 (28.9%)		16 (59.3%)	16 (29.1%)

*p < 0.05.